extensive post-market safety data Advantage : Tirzepatide Liver Fat Reduction# Retatrutide : Significant hepatic fat reduction via glucagon receptor activation (up to 82% reduction) Tirzepatide : Moderate hepatic fat reduction observed in trials Advantage : Retatrutide Dosing Convenience# Retatrutide : Once-weekly subcutaneous injection Tirzepatide : Once-weekly subcutaneous injection with established titration schedule Advantage : Neither (tie) Summary and Verdict# Tirzepatide is the proven choice with FDA approval and extensive clinical data
9 Conclusion GLP-1 receptor agonists have emerged as revolutionary therapeutic agents in the treatment of T2DM and obesity, exhibiting significant effectiveness via their multi-faceted activities
But some previous clinical trials found that people lost up to 20% of their body weight while on these GLP-1 drugs
Ozempic (semaglutide) suppresses appetite through GLP-1 receptor activation, reducing hunger signals in the brain
The prescribing provider understands the full medical picture and may have context about the rate of weight loss or other factors that are relevant
The practical drivers we see most often are simpler than brain chemistry: rapid change, lower energy, under-eating, nausea, and shifting body image
